- Home
- NMRA vs CERS Comparison
NMRA vs CERS Comparison
Compare NMRA & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- CERS
- Stock Information
- Founded
- NMRA 2019
- CERS 1991
- Country
- NMRA United States
- CERS United States
- Employees
- NMRA N/A
- CERS N/A
- Industry
- NMRA
- CERS EDP Services
- Sector
- NMRA
- CERS Technology
- Exchange
- NMRA Nasdaq
- CERS Nasdaq
- Market Cap
- NMRA 268.5M
- CERS 237.7M
- IPO Year
- NMRA 2023
- CERS 1997
- Fundamental
- Price
- NMRA $1.62
- CERS $1.27
- Analyst Decision
- NMRA Buy
- CERS Strong Buy
- Analyst Count
- NMRA 8
- CERS 2
- Target Price
- NMRA $7.14
- CERS $3.50
- AVG Volume (30 Days)
- NMRA 931.0K
- CERS 1.2M
- Earning Date
- NMRA 08-06-2025
- CERS 08-05-2025
- Dividend Yield
- NMRA N/A
- CERS N/A
- EPS Growth
- NMRA N/A
- CERS N/A
- EPS
- NMRA N/A
- CERS N/A
- Revenue
- NMRA N/A
- CERS $192,510,000.00
- Revenue This Year
- NMRA N/A
- CERS $24.95
- Revenue Next Year
- NMRA N/A
- CERS $11.88
- P/E Ratio
- NMRA N/A
- CERS N/A
- Revenue Growth
- NMRA N/A
- CERS 13.25
- 52 Week Low
- NMRA $0.61
- CERS $1.12
- 52 Week High
- NMRA $17.19
- CERS $2.39
- Technical
- Relative Strength Index (RSI)
- NMRA 51.72
- CERS 47.80
- Support Level
- NMRA $1.56
- CERS $1.23
- Resistance Level
- NMRA $1.78
- CERS $1.38
- Average True Range (ATR)
- NMRA 0.12
- CERS 0.07
- MACD
- NMRA -0.03
- CERS -0.00
- Stochastic Oscillator
- NMRA 58.97
- CERS 50.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.